Last reviewed · How we verify
L19IL2 + L19TNF
L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.
L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment. Used for Metastatic melanoma, Metastatic renal cell carcinoma.
At a glance
| Generic name | L19IL2 + L19TNF |
|---|---|
| Sponsor | Philogen S.p.A. |
| Drug class | Bispecific antibody-cytokine fusion |
| Target | Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
L19 is a human recombinant antibody that selectively binds to the extra domain B (EDB) of fibronectin, which is highly expressed in tumor vasculature but absent in normal adult tissues. IL2 (interleukin-2) and TNF (tumor necrosis factor) are fused to this antibody, allowing targeted delivery of these immunostimulatory cytokines directly to tumors. This approach combines vascular targeting with localized immune activation to enhance anti-tumor immunity while minimizing systemic toxicity.
Approved indications
- Metastatic melanoma
- Metastatic renal cell carcinoma
Common side effects
- Fever
- Chills
- Fatigue
- Hypotension
- Elevated liver enzymes
Key clinical trials
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (PHASE2)
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (PHASE2)
- L19IL2/TNF in Patients With Basal Cell Carcinoma (PHASE2)
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (PHASE3)
- Efficay and Safety of DAROMUN on Patient Treated by Intralesionnal Injection: DAROMEL
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (PHASE2)
- Neoadjuvant L19IL2/L19TNF- Pivotal Study (PHASE3)
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19IL2 + L19TNF CI brief — competitive landscape report
- L19IL2 + L19TNF updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI